Junshi Biosciences Shareholder Plans Up to 2% Stake Reduction

Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has shared an announcement.

Shanghai Junshi Biosciences announced that shareholder Shanghai Tanying Investment Partnership (LP), a private equity fund and pre-IPO investor, currently holds 59,459,326 A shares, representing 5.7914% of the company’s total share capital, with these shares freely tradable since July 2021. Owing to fund maturity and liquidity needs, Shanghai Tanying plans to trim its stake by up to 20,533,797 shares, or no more than 2% of the company’s total share capital, via block trades, signaling a portfolio adjustment rather than a shift in its stated long-term positive view of Junshi’s prospects and providing the market with clarity on potential share overhang.

The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.

More about Shanghai Junshi Biosciences Co., Ltd. Class H

Shanghai Junshi Biosciences Co., Ltd. is a PRC-incorporated biopharmaceutical company listed in Hong Kong and on Shanghai’s STAR Market. The company focuses on innovative drug R&D and commercialization, serving China’s healthcare market and international investors through dual listings in major capital markets.

Average Trading Volume: 4,201,539

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$44.49B

For an in-depth examination of 1877 stock, go to TipRanks’ Overview page.